Elevation Oncology (NASDAQ:ELEV – Free Report) had its price objective trimmed by HC Wainwright from $6.00 to $1.00 in a ...

HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Avalo Therapeutics in a research report issued to ...

Lyell Immunopharma’s (LYEL) jumped over 8% on Friday as investors’ interest surged. Despite posting unimpressive Q4 results a ...

Fintel reports that on March 21, 2025, HC Wainwright & Co. downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Buy to ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Barinthus Biotherapeutics (BRNS – Research Report) today and set a price target of ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

On Friday, H.C. Wainwright reaffirmed a Neutral stock rating for Adicet Bio Inc. (NASDAQ:ACET), a biotechnology company focused on the development of therapies for cancer and other diseases.

Fireside chat Damian Marron, interim CEO, will participate in a fireside chat moderated by Joe Pantginis, Managing Director, Equity Research at H.C. Wainwright & Co., LLC. March 27 at 08.00am EST ...